![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Context: Epigenetic alterations in suppressor of cytokine signalling 3 (SOCS3) have been suggested as a potential biomarker in glioma.
Objective: To investigate whether SOCS3 methylation could act as a biomarker for glioma grading and prognosis.
Materials and methods: Glioma samples were evaluated by pyrosequencing and quantitative reverse transcription-polymerase chain reaction (qRT-PCR).
Results: SOCS3 promoter methylation was more frequent in the WHO III and (anaplastic) oligoastrocytomas group. SOCS3 methylation status was significantly inversely correlated with mRNA expression level. Mutant IDH1 caused marked increase in SOCS3 methylation.
Conclusion: SOCS3 methylation is a potential biomarker for grading and prognosis in human glioma.
Acknowledgements
The authors would like to thank Tangdu Hospital for collecting and providing the tissue samples used in this study.
Disclosure statement
The authors declare that they have no conflict of interest.
Funding information
This work was financially supported by the National Natural Science Foundation of China (31271353) and the Natural Science Foundation of Shaanxi Province (FH11123).